title: Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores.
abstract: Fidaxomicin (FDX) is approved to treat Clostridium difficile-associated diarrhea and is superior to vancomycin in providing a sustained clinical response (cure without recurrence in the subsequent 25 days). The mechanism(s) behind the low recurrence rate of FDX-treated patients could be multifactorial. Here, we tested effects of FDX, its metabolite OP-1118, and vancomycin on spore germination and determined that none affected the initiation of spore germination but all inhibited outgrowth of vegetative cells from germinated spores.
authors.affiliation: Department of Biology, Texas A&M University, College Station, Texas, USA.
authors.forename: Charlotte A
authors.initials: CA
authors.lastname: Allen
authors.forename: Farah
authors.initials: F
authors.lastname: Babakhani
authors.forename: Pam
authors.initials: P
authors.lastname: Sears
authors.forename: Ly
authors.initials: L
authors.lastname: Nguyen
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sorg
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects* / Q000254:growth & development; D003470:Culture Media; D000077732:Fidaxomicin; D008826:Microbial Sensitivity Tests; D013171:Spores, Bacterial / Q000187:drug effects* / Q000254:growth & development; D013656:Taurocholic Acid / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003470:Culture Media; C561044:OP-1118; D013656:Taurocholic Acid; D014640:Vancomycin; D000077732:Fidaxomicin